The Other Epidemic: Stimulant Use Disorders

This presentation will describe the local and national scope of stimulant use disorders including current trends in use amongst special populations (e.g., adolescents, women, criminal justice populations, racial/ethnic minorities, and LGBT individuals). The mental health and physical health consequences of stimulant use disorders will be presented including information on stimulant use and its impact on the brain and cognition. Methamphetamine use, and psychosis/ psychiatric comorbidity will also be explored. The presentation will conclude with a discussion on how to implement effective treatment interventions to people who use stimulants and the necessary adaptations needed to engage and retain special populations in care. Effective behavioral treatments for stimulant use tailored to stage of treatment will be discussed.

This presentation is intended to assist Substance Use Disorder providers in identifying and addressing real world considerations in effectively engaging patients in care, making level of care determinations for Stimulant Use Disorders and practical treatment and programmatic approaches to treatment.

Objectives: At the end of this presentation, participants will be able to:

Describe the local and national scope of stimulant use, including use among special populations (e.g., adolescents, women, criminal justice, LGBT individuals, etc.).

Evaluate at least three (3) similarities and differences between the types of Stimulants including Amphetamines, Methamphetamines, and Cocaine.

List at least three (3) short-term and long-term effects of Stimulant Use Disorders and common associated medical complications

Utilize understanding of treatment goals to identify three (3) treatment options for Stimulant Use Disorders.


thomas freese

THOMAS FREESE, Ph.D. is Director of Training for UCLA Integrated Substance Abuse Programs. He serves as Principal Investigator of the Conrad N. Hilton Foundation Youth SBIRT Training and Technical Assistance Grant, and Director of the Pacific Southwest Addictions Technology Transfer Center, funded by SAMHSA. Dr. Freese has conducted worldwide trainings on topics that include implementing integrated treatment, SBIRT, medication-assisted treatment, methamphetamine use, addressing the opioid epidemic, and culturally-responsive treatment for LGBTQ clients.

This conference meets the qualifications for the provision of six (6.0) continuing education credits/contact hours (CEs/CEHs). UCLA Integrated Substance Abuse Programs (ISAP) is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for LMFTs, LCSWs, LPCCs, and/or LEPs (Provider #64812). UCLA ISAP maintains responsibility for this program/course and its content. This conference meets the qualifications for six (6.0) hours of continuing education credit for LMFTs, LCSWs, LPCCs, and LEPs as required by the California Board of Behavioral Sciences. UCLA ISAP is also an approved provider of continuing education for RADTs I/II, CADCs-CASs, CADCs I/II, CADCs-CSs, and LAADCs (CCAPP, #2N-00-445-1119), CATCs (ACCBC, #CP 20 872 C 0819), and CAODCs (CADTP, #151). CE credit will be awarded at the conclusion of the conference. Partial credit will not be available for those participants who arrive late or leave early.